NDMA attapulgite study
This article was originally published in The Tan Sheet
Executive Summary
Protocol submitted to FDA on April 8 to support the efficacy of attapulgite for treatment of acute nonspecific diarrhea. NDMA said that the protocol provides several options for proceeding with the study and that it is awaiting comment from FDA on which options would be preferable. FDA and NDMA met to discuss the attapulgite study at a recent feedback meeting ("The Tan Sheet" Jan. 31, p. 8)
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning